CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-20 | Heyman Richard A. Director | Sale 10b5-1 | −512 | $26.46 | $14K | 24,595 |
| 2026-01-20 | Heyman Richard A. Director | Sale 10b5-1 | −718 | $26.96 | $19K | 23,877 |
| 2026-01-09 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −48,057 | $27.98 | $1.3M | 215,254 |
| 2026-01-09 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −243 | $28.50 | $7K | 215,011 |
| 2026-01-09 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −41,198 | $24.90 | $1.0M | 815,188 |
| 2026-01-09 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −50,000 | $29.13 | $1.5M | 765,188 |
| 2026-01-09 | Heyman Richard A. Director | Sale 10b5-1 | −4,285 | $25.00 | $107K | 25,107 |
| 2026-01-08 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −7,500 | $20.13 | $151K | 890,188 |
| 2026-01-08 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −33,802 | $24.92 | $842K | 856,386 |
| 2026-01-08 | Heyman Richard A. Director | Sale 10b5-1 | −1,620 | $25.00 | $41K | 25,545 |
| 2026-01-08 | Heyman Richard A. Director | Sale 10b5-1 | −8,015 | $25.04 | $201K | 29,392 |
| 2026-01-07 | Garland J. Scott Director | Grant or award · Stock Option (right to buy) | +59,372 | 59,372 | ||
| 2025-12-22 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise | +13,000 | $2.48 | $32K | 36,000 |
| 2025-12-22 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) | −13,000 | 92,056 | ||
| 2025-12-19 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −5,000 | $16.84 | $84K | 897,688 |
| 2025-12-17 | Kunkel Lori Anne Director | Option exercise | +15,958 | $1.12 | $18K | 30,712 |
| 2025-12-17 | Kunkel Lori Anne Director | Option exercise · Stock Option (right to buy) | −15,958 | 3,741 | ||
| 2025-12-11 | Fair Richard A. PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +875,000 | 875,000 | ||
| 2025-12-08 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −4,958 | $20.76 | $103K | 265,016 |
| 2025-12-08 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −1,705 | $21.78 | $37K | 263,311 |
Page 7 of 37 · 724 trades